The Impact of GLP-1 Receptor Agonists on Breastfeeding: Insights from Experts

Welcome back to the Doc Who Lift podcast! In this episode, Dr. Spencer Nadolsky and co-host Dr. Carl celebrate Dr. Carl's birthday and welcome a special guest, Dr. Caitlyn Crutch, a renowned researcher from Texas Tech University. Dr. Crutch shares her expertise on GLP-1 receptor agonists—medications gaining popularity for weight management and type 2 diabetes—and their implications for breastfeeding mothers.

Introduction to GLP-1 Receptor Agonists

GLP-1 receptor agonists, including medications like semaglutide and tirzepatide, have been extensively studied for their roles in diabetes management and weight loss. However, a critical concern for many breastfeeding mothers is whether these medications can safely be used while nursing. Dr. Crutch sheds light on the current understanding of how these drugs transfer into breast milk and their potential effects on infants.

Dr. Caitlyn Crutch’s Background

Dr. Crutch has an impressive background, holding degrees in pharmacy, nutrition, business, and research. As the director of the Infant Risk Center, she has focused on how various medications, including GLP-1 receptor agonists, transfer into breast milk. Her work is pivotal in providing evidence-based guidance for lactating mothers taking these medications.

Research on GLP-1 Medications and Breast Milk

Dr. Crutch discusses her research on GLP-1 receptor agonists. Despite the popularity of these medications, there remains a significant lack of lactation data for most drugs. The FDA has started to take a greater interest in this area, leading to a need for more comprehensive studies.

Findings from Recent Studies

Dr. Crutch's research has shown that:

• Semaglutide was not detectable in breast milk in any participants taking the drug.
• Tirzepatide showed very low levels in breast milk, with the relative infant dose being below 0.05%—far below the 10% threshold typically considered safe.

Considerations for Breastfeeding Mothers

As breastfeeding mothers consider the use of GLP-1 medications, Dr. Crutch emphasizes the following:

• While the risk appears low based on current data, individual circumstances should be considered, particularly regarding the mother's nutritional intake and overall health.
• Weight management post-delivery is a sensitive topic. Mothers should be cautious about the potential impact of these medications on their milk supply.
• Consultation with healthcare providers is crucial to make informed decisions regarding medication use during breastfeeding.

Conclusion

Dr. Caitlyn Crutch’s insights provide valuable guidance for healthcare providers and breastfeeding mothers considering GLP-1 receptor agonists. As research continues to evolve, it is essential to stay informed about the safety and implications of these medications during lactation.

To hear more from Dr. Crutch and learn about the latest research, be sure to check out her published papers and resources available through the Infant Risk Center.

Key Takeaways

• GLP-1 receptor agonists like semaglutide and tirzepatide have low levels in breast milk and are unlikely to pose a significant risk to breastfeeding infants.
• Breastfeeding mothers should consult healthcare providers when considering these medications.
• Nutrition and milk supply are critical considerations when using GLP-1 medications during breastfeeding.

TLDR Summary

GLP-1 receptor agonists, including semaglutide and tirzepatide, show minimal transfer into breast milk, posing little risk to breastfeeding infants. However, mothers should discuss their use with healthcare providers to ensure their health and nutritional needs are met.

Authors

• Dr. Spencer Nadolsky
• Dr. Carl
• Dr. Caitlyn Crutch